Vertex Pharmaceuticals Inc. (VRTX)
Vertex Pharmaceuticals Inc. reported revenue of $12.00B for the fiscal year ended Dec 31, 2025, up 8.9% from $11.02B the year before. Net income was $3.95B, a net margin of 32.9% (prior year: −$535.60M). At the end of that fiscal year the company reported total assets of $25.64B and shareholders' equity of $18.67B.
Revenue
$12.00B
+8.9% vs prior year
Net income
$3.95B
Net margin 32.9%
Diluted EPS
$15.32
USD per share
Total assets
$25.64B
At Dec 31, 2025
Equity
$18.67B
At Dec 31, 2025
Shares outstanding
254M
As of Oct 31, 2026
Explore Vertex Pharmaceuticals Inc.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Nov 3, 2026
- 10-QFiled Aug 4, 2026
- 10-QFiled May 5, 2026
- 10-KFiled Feb 13, 2026
- 10-QFiled Nov 4, 2025
- 10-QFiled Aug 5, 2025
Source: SEC EDGAR XBRL company facts for CIK 875320 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.